Psoriasis Enrollment Completed 14 Weeks Ahead of Schedule
Case Study
Sep 20, 2019
IQVIA™ Biotech’s patient recruitment process and predictive enrollment expertise can dramatically reduce enrollment timelines
A leading global pharmaceutical company with a focus on dermatology selected IQVIA Biotech to conduct a large Phase III psoriasis study involving over 1,100 patients at 60 sites. The dermatology team was challenged to achieve the sponsor’s goal of randomizing 1,152 patients in a nine-month period. Our patient recruitment process and predictive enrollment expertise dramatically reduced enrollment timelines by 44% and budget was maintained.